CLAIMS

1. Use of *Mentha arvensis* extract in the ~~manufacturing~~ manufacture of a ~~composition~~ medicament for ~~caring~~treating damages of skin cells by microdust,

wherein the ~~composition~~ medicament inhibits the expression of ~~at least one gene selected from the group consisting of IL-1a (NM_000575), IL-1B (NM_000576),~~ IL-36G (NM_019618), S100A7 (NM_002963), LCE3D (NM_032563), PTGS2 (NM_000963), and XDH (NM_000379).

2. The use according to claim 1,

wherein the ~~caring~~treating damages of skin cells by microdust is at least one selected from the group consisting of treating or improving atopic dermatitis, psoriasis, ~~enhancement of the skin barrier, anti-aging~~ and anti-inflammation.

3. Use of *Mentha arvensis* extract in the ~~manufacturing~~ manufacture of a ~~composition~~ medicament for ~~enhancing the skin barrier~~treating or improving atopic dermatitis or psoriasis,

wherein the medicament~~composition~~ inhibits the expression of ~~at least one gene selected from the group consisting of~~ IL-36G (NM_019618), S100A7 (NM_002963), and LCE3D (NM_032563).

~~4. Use of *Mentha arvensis* extract in manufacturing a composition for anti-aging,~~

~~wherein the composition inhibits the expression of at least one gene selected from the group consisting of IL-1a (NM_000575), IL-1B (NM_000576), PTGS2 (NM_000963), and XDH (NM_000379).~~

4~~5~~. Use of *Mentha arvensis* extract as an active ingredient in the ~~manufacturing~~ manufacture of a ~~composition~~ medicament for anti-inflammation,

wherein the medicament~~composition~~ inhibits the expression of ~~at least one gene selected from the group consisting of IL-1a (NM_000575), IL-1B (NM_000576), and~~ PTGS2 (NM_000963).

5~~6~~. The use according to any one of claims 1 to 4~~5~~,

wherein the content of the *Mentha arvensis* extract is 0.000001 to 30% by weight based on the total weight of the medicament~~composition~~.

6~~7~~. The use according to any one of claims 1 to ~~5~~4,

wherein the *Mentha arvensis* extract is extracted with at least one extraction solvent selected from the group consisting of water, C_1–C_6 anhydrous or hydrated lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and hexane.

7~~8~~. The use according to any one of claims 1 to ~~5~~4,

wherein the *Mentha arvensis* extract is extracted from the leaves of *Mentha arvensis*.

8~~9~~. The use according to any one of claims 1 to ~~5~~4,

wherein the *Mentha arvensis* is fermented *Mentha arvensis*, and

the fermentation is carried out by adding a microorganism of the genus *Acetobacter sp*.

9~~10~~. The use according to claim ~~9~~8,

wherein the microorganism of the genus *Acetobacter sp*. is *Acetobacter aceti*.

10~~11~~. The use according to any one of claims 1 to ~~5~~4,

wherein the medicament~~composition~~ inhibits the expression of the genes in keratinocytes.

11~~12~~. The use according to any one of claims 1 and 3 to 4, wherein the *Mentha arvensis* extract is to be administered at a dose of 10 to 500 mg/kg/day.

~~13. The use according to any one of claims 1 to 5, wherein the composition is a cosmetic composition.~~

~~14. The use according to any one of claims 1 to 5, wherein the composition is a pharmaceutical composition.~~

~~15. The use according to any one of claims 1 to 5, wherein the composition is a health functional food composition.~~